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Abstract
Background: Polycystic ovary syndrome (PCOS) is considered as one of the most frequently encountered hormonal
pathologies in women during their reproductive years. Leptin and ghrelin, peptide hormones with adipostatic and
orexigenic effect, respectively, seem to be involved in the metabolic changes that occur in PCOS. The aim of this study
was to determine serum ghrelin and leptin levels in obese and lean Saudi women with PCOS and to investigate their
relationship to the metabolic profiles in these women.
Methods: This study was conducted as a prospective, observational, cross-sectional, case-control study, at the
Department of Obstetrics and Gynecology, Al-Noor Hospital, Makkah, Kingdom of Saudi Arabia. The study population
included 252 women [130 women with PCOS (diagnosed according to the Rotterdam ESHRE/ASRM-Sponsored PCOS
Consensus, 2003) and 122 normo-ovulatory women as matched controls] attending the outpatient Gynecology Clinic.
Demographic details were recorded, blood was extracted following overnight fast and serum was used for the
determination of serum ghrelin and leptin levels and other hormonal and biochemical parameters including total
cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol,
glucose, and insulin. Insulin resistance and sensitivity were calculated as HOMA-IR and HOMA-S.
Results: No significant differences in ghrelin (P = 0.1830) and leptin (P = 0.8329) levels were detected between
the PCOS and control groups. However, ghrelin levels were significantly lower; and leptin levels were significantly
higher in obese PCOS patients in comparison with lean patients (P = 0.0001 for both). In the PCOS group, there
were significant correlations between ghrelin and leptin levels with Body Mass Index (BMI), waist-hip ratio, total
cholesterol, triglycerides, HDL, LDL and insulin levels. Multiple regression analysis demonstrated that insulin was
the main determinant for ghrelin (R2 = 0.316) and leptin (R2 = 0.352) levels (P = 0.0001 for both).
Conclusions: Although serum ghrelin and leptin levels were found to be normal in women with PCOS; yet, there
is a relationship, possibly linked to obesity, hyperinsulinemia and insulin resistance between these levels and metabolic
profile of Saudi PCOS.
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Background
In 1935, Stein and Leventhal first described polycystic
ovary syndrome (PCOS) in seven women suffering from
amenorrhea, enlarged ovaries with multiple cysts, and
hirsutism [1]. Currently, PCOS is considered as one of
the most frequently encountered hormonal pathologies
in women during their reproductive years, occurring in
most populations of the World [2, 3] and prevalence as
high as 15–20% has been reported in some studies [4]. It
is a heterogeneous complex genetic trait of multifactorial
nature where both genetic and environmental factors
contribute to the underlying pathophysiological mecha-
nisms [5]. It has drawn significant attention as it is con-
sidered as a major cause of anovulatory infertility in
women of childbearing age, and is the cause of several
other complications including endocrine, metabolic,
hemostatic and hepatic derangements [6, 7]. These re-
cent studies have highlighted the association between
PCOS and metabolic syndrome, obesity, insulin resist-
ance, cardiovascular diseases and liver diseases including
cirrhosis, liver tumors and fatty liver [6, 8].
Obesity is considered as one of the major factor pre-
disposing to the development of PCOS, since 35-80% of
the women suffering from PCOS are reported to be
overweight or obese [9–12]. However, it is not the only
factor, since many PCOS patients are lean [13, 14]. Type
1 and Type 2 diabetes mellitus, and gestational diabetes
have been associated with an increased prevalence of
PCOS [15]. Some studies have implicated leptin and
ghrelin as possible factors contributing to the develop-
ment of PCOS, while others have failed to do so [16–
19]. Leptin, a polypeptide hormone, functions as an adi-
postatin, where it suppresses food intake and activates
catabolic pathways associated with increased energy pro-
duction [20, 21]. It also plays a role in improving the in-
sulin sensitivity of the peripheral tissues and affects
beta-cell functions. Leptin signaling is involved in obes-
ity and its cardiovascular complications [22]. It also af-
fects reproductive functions at many levels, where it is
shown to inhibit folliculogenesis, influences embryo im-
plantation and endometrial receptivity [23–25]. Since
obesity is associated with hyperleptinaemia, the situation
in obese PCOS becomes more complex [25, 26]. Ghrelin,
another peptide hormone, has an orexigenic effect [27].
It also stimulates growth hormone secretion, regulates
glucose metabolism, appetite, body weight, endocrine
pancreatic, and ovarian functions [28, 29]. It exhibits a
negative correlation with androstenedione, and in obese
women with PCOS, it may contribute to modification of
factors such as insulin resistance and androgens, hence
producing a negative effect on fertility [12]. Ghrelin
levels are shown to be lower in PCOS, and this decrease
has been associated with the negative correlation shown
between body mass index (BMI) and ghrelin [30].
Several studies show contradictory results in the level of
ghrelin in PCOS patients, where lower ghrelin levels
have been reported in some studies, while others report
that there was no change in ghrelin level in PCOS, [4, 5,
31, 32]. An earlier study from our group, on a smaller
number of Saudi PCOS patients, failed to show the ex-
istence of hypoghrelinaemia [19].
Several metabolic and hormonal dysfunctions exist in
patients suffering from PCOS, and these include insulin
resistance, glucose intolerance, and dyslipidemia [33, 34].
Hyperinsulinaemia is frequently reported in PCOS and
may be involved in anovulation, by causing premature
maturation of granulosa cells, inhibition of granulosa cell
proliferation and development in the presence of elevated
LH levels [35]. Furthermore, some studies have shown
that insulin resistance and neuroendocrine dysfunctions
play a significant role in the pathogenesis of PCOS [36].
In Saudi females, PCOS occurs frequently, but the
exact prevalence is not known. Some recent studies have
reported variations in the levels of metabolic and hor-
monal parameters [19]. However, more extensive studies
are warranted, in order to achieve a clearer picture of
the disease and to identify further underlying etiological
factors contributing to the development of PCOS in the
Saudi population.
We designed this study as a case-control study on
Saudi PCOS patients in an attempt to determine leptin
and ghrelin levels and to investigate the type of relation-
ship that exists between these hormones and anthropo-
metric, metabolic and hormonal parameters. The study
was conducted in two stages, where initially (stage 1) the
results in the PCOS were compared to the control group
and in the stage 2, a comparison was made between the
lean and obese PCOS. This paper reports the findings of
this study in Saudi Arabia and compares the results with
those reported for other populations.
Methods
Subject recruitment and type of study
The present investigation was conducted as a prospect-
ive, observational, cross-sectional, case-control study at
the Department of Obstetrics and Gynecology, Al-Noor
Hospital, Makkah, Kingdom of Saudi Arabia. The local
Ethical Committee approved the study protocol (Review
Board (IRB) at the Umm Al Qura University, Makkah Al
Mukaramah, Saudi Arabia (IRB No. 235) and 252 fe-
males, who were attending the outpatient Gynecology
Clinic, were enrolled in the present investigation, after
taking their informed consent.
Of the total females enrolled, 130 patients were diag-
nosed as suffering from PCOS group according to the
Rotterdam Consensus guidelines [4], based on the asso-
ciation of at least two of the three following criteria:
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(1) Oligo- and/or anovulation; confirmed by luteal
progesterone and normal serum FSH levels
(normal range: 1.0–10.0 mIU/ml).
(2) Clinical and/or biochemical signs of raised androgens;
elevated serum androgen levels (total testosterone
> 2 nmol/l), and/or androstenedione > 0.15 nmol/l,
and/or dehydroepiandrosterone sulphate (DHEAS)
> 10 mmol/l); LH to FSH ratio > 2.
(3) Ultrasound criterion of PCOS; at least one ovary
containing > 12 follicles measuring 2–9 mm in
diameter and/or increase in the ovarian volume to
at least 10 ml [4, 37].
The control group consisted of 121 normo-ovulatory
women with male, tubal or unexplained infertility. They
had regular ovulatory cycles (25–35 days), no endocrine
abnormalities, no clinical or biochemical signs of raised
androgens, and normal ultrasonic ovarian morphology.
The control women were matched with PCOS patients
for age (± 2 years SD) and body mass index, BMI (± 10%).
Exclusion criteria for all the subjects included preg-
nancy, hypothyroidism, hyperprolactinemia, Cushing’s
syndrome, congenital adrenal hyperplasia, current or pre-
vious (within the last 6 months) use of oral contraceptives,
glucocorticoids, antiandrogens, ovulation induction
agents, antidiabetic and anti-obesity drugs or other hor-
monal pharmaceuticals. None of the patients was affected
by neoplastic, metabolic and cardiovascular disorder or
other concurrent medical illness such as diabetes, renal
disease, and hepatic disorders. All the subjects were
non-smokers and had normal physical activity.
Anthropometric measurements
For each woman weight and height were measured and
the BMI (weight in kg divided by height in m2) were cal-
culated. Considering our anthropometric local data on the
Saudi female population, patients with a BMI > 27 kg/m2
were considered obese, and those with a BMI ≤27 were
considered lean. Waist circumference (the narrowest cir-
cumference between the lower costal margins and the iliac
crest) and hip circumference (the maximum circumfer-
ence at the level of the femoral trochanters) were also
measured in the standing position to calculate the
waist-hip ratio (WHR).
Biochemical measurements
A peripheral venous blood sample was extracted in the
morning after overnight fasting. During the early follicu-
lar phase (2nd or 3rd day), 5 ml of blood was drawn in
plain red-top tubes for serum on which the determin-
ation of leptin, cholesterol, triglyceride, HDL-C, LDL-C,
insulin levels was accomplished within the next 4 h
(max) following the blood withdrawal. Two ml of blood
were collected into chilled tubes containing 1.2 mg
EDTA and aprotinin (500 KIU/ml; Trasylol; Bayer Corp.,
Leverkusen, Germany) for total ghrelin levels and 2 ml
were drawn in fluoride tubes (gray top) for glucose esti-
mation. All blood samples for each woman were imme-
diately centrifuged, and the serum or plasma was stored
at − 80 °C until further analysis.
The basal serum levels of insulin were estimated using
the electrochemiluminescence immunoassay “ECLlA” on
a Roche Elecsys 1010/2010 and Modular Analytics E170
(Elecsys module) immunoassay analyzers (Roche Diag-
nostic, Mannheim, Germany). Total ghrelin levels were
measured in duplicate using a commercial ghrelin
(human)-enzyme immunoassay kit (EIA) from Phoenix
Pharmaceuticals, Inc.,(Belmont, CA, USA), with a lower
limit of detection of 0.06 ng/ml. Plasma glucose levels were
determined by the glucose oxidase method on a Beckman
Glucose Analyzer (Fullerton, CA). Lipids were determined
on an autoanalyzer for clinical chemistry in the hospital.
Homeostatic model assessment of insulin resistance
(HOMA-IR) and insulin secretion were calculated using
the following formulas:
Insulin resistance ¼ FIG
22:5
Insulin secretion ¼ 20 FI
G‐3:5
HOMA-IR = Fl X G/ 22.3
HOMA-S = 20 X-FI/G-3.5
Where FI is fasting insulin and G is fasting glucose.
Statistics
Data was collected and entered into a spreadsheet, to
evaluate their organization and inference with proper
statistical assays, where all analyses were performed
using Statistical Package for the Social Science, version
22 (SPSS; Inc., Chicago, IL, USA). Results were
expressed as mean ± SD and compared using ANOVA in
a student’s t-test or a Wilcoxon-Mann-Whitney U-test
when appropriate, following a Shapiro-Wilk test for nor-
mality. Correlations between ghrelin, leptin, HOMA-IR
and HOMA-S levels and the anthropometric measure-
ments, lipid, and hormonal parameters were performed
and evaluated using Pearson correlation coefficient (r).
Multiple regression analysis was used to evaluate the
preferential effect of the different studied variables on
ghrelin, leptin, HOMA-IR and HOMA-S levels. A p-value
< 0.05 was considered statistically significant. Data from
this study were also approached to build up a ROC curve
analysis for the determination of the best suited predictive
marker of PCOS in obese Saudi women.
Results
Anthropometric data and metabolic profile of patients
with PCOS and controls are summarized in Table 1.
There were no statistically significant differences in the
leptin and ghrelin levels between the two investigated
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groups. In the PCOS group, the WHR, cholesterol,
triglyceride, LDL-C and insulin levels were significantly
higher and HDL-C levels were significantly lower in
comparison with the control group (p < 0.0001). Insulin
resistance as indicated by the higher HOMA-IR was
significantly more in the PCOS compared to the con-
trols, but the insulin secretion as judged from the
value of HOMA-S was not different between the two
groups.
The lean and obese PCOS and control were separated,
and all the parameter values were recalculated and com-
pared to the PCOS (either lean or obese) patients and
controls. The results are presented in Table 2.
When the lean PCOS were compared with the obese
PCOS, all studied parameters including leptin, ghrelin,
and HOMA-IR, except HDL level and HOMA-S showed
statistically significant differences. However, this differ-
ence was not statistically significant when all PCOS pa-
tients were compared with controls. On the other hand,
all the parameters were different statistically when the
lean control values were compared with the values ob-
tained in the obese controls, as shown in Table 2. The
differences were still significant statistically when the
values in lean PCOS were compared to the lean control,
except for HOMA-S, which did not differ significantly.
However, when the values in obese PCOS were com-
pared to the values in obese control, certain parameters
lost the significant difference. These included BMI,
HDL-C, leptin, ghrelin, insulin and HOMA-S.
Table 2 shows leptin and ghrelin levels in lean and
obese patients with PCOS compared to controls.
Ghrelin levels were significantly lower, and leptin
levels were significantly higher in obese patients with
PCOS and obese controls in comparison with lean
patients with PCOS and lean controls (P < 0.0001 for
each). Likewise, ghrelin levels were significantly lower
(P = 0.0249), and leptin levels were significantly
higher (P = 0.0019) in lean patients with PCOS in
comparison with lean controls. However, there was
no statistically significant difference in ghrelin levels
(P = 0.767) and leptin levels (P = 0.181) in obese pa-
tients with PCOS and obese controls.
Correlation of leptin levels to the clinical and meta-
bolic profile of patients with PCOS and controls is pre-
sented in Table 3. In the PCOS group, leptin levels did
not correlate with age and glucose levels, however, there
was a significant positive correlation with BMI, WHR,
cholesterol, triglyceride, LDL-C and insulin levels and a
significant negative correlation with HDL-C and ghrelin
levels. In the control group, there was only a significant
positive correlation with BMI and insulin levels; and a
significant negative correlation with ghrelin levels while
other parameters did not correlate with leptin levels.
Multiple regression analysis demonstrated that insulin
was the primary determinant of leptin level in the PCOS
group (R2 = 0.352; P = 0.0001).
Correlation of ghrelin levels to the clinical and meta-
bolic profile of patients with PCOS and controls is pre-
sented in Table 4. In the PCOS group, ghrelin levels did
not correlate with age and glucose levels; however, there
was a significant negative correlation with BMI, WHR,
cholesterol, triglyceride, LDL-C, insulin, leptin levels,
HOMA-IR and HOMA-S; and a significant positive cor-
relation with HDL-C levels. In the control group, only a
significant negative correlation with BMI, insulin, leptin
levels and HOMA-IR and HOMA-S was observed, while
other parameters did not correlate with ghrelin levels.
Multiple regression analysis demonstrated that insulin
was the primary determinant of ghrelin level in the
PCOS group (R2 = 0.316; P < 0.0001).
Table 1 Comparison of anthropometric measurements and
metabolic profile of patients with polycystic ovary syndrome
(POCS) and normal healthy females
Groupa Mean SD p
Age (years) PCOS 25.61 0.39 0.135
Control 24.67 0.50
Body mass index (BMI) (kg/m2) PCOS 28.66 0.58 0.339
Control 27.77 0.73
Weight/height ratio PCOS 0.84 0.008 < 0.0001
Control 0.76 0.007
Cholesterol (mmol/L) PCOS 4.32 0.07 < 0.0001
Control 3.64 0.05
Triglyceride (mmol/L) PCOS 1.08 0.03 < 0.0001
Control 0.86 0.03
HDL-C (mmol/L) PCOS 1.08 0.02 < 0.0001
Control 1.27 0.03
LDL-C (mmol/L) PCOS 2.44 0.05 < 0.0001
Control 1.71 0.05
Leptin (ng/ml) PCOS 25.56 1. 37 0.833
Control 26.05 1.84
Ghrelin (ng/ml) PCOS 0.42 0.013 0.200
Control 0.45 0.015
Insulin (pmol/L) PCOS 97.98 5.20 < 0.0001
Control 73. 37 3.48
Glucose (mmol/L) PCOS 5.05 0.045 < 0.0001
Control 4.71 0.045
HOMA-IR (insulin resistance) PCOS 3.23 0.18 < 0.0001
Control 2.28 0.11
HOMA-S (insulin sensitivity) PCOS 180.66 10.07 0.770
Control 184.70 9.32
Groupa = PCOS- 130; Control- 122
SEM Standard error of the mean; p = < 0.05 is statistically significant
HOMA Homeostatic model assessment
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The HOMA-IR and HOMA-S were correlated with
the clinical and biochemical parameters, and the results
are presented in Tables 5 and 6, respectively.
ROC analysis of PCOS patients either without or with
obesity diagnosis (lean) for all the parameters investi-
gated and the relative values are shown respectively in
Additional file 1: Figures S1, S2 and S3 and Additional
file 2: Tables S1, S2 and S3.
Discussion
The results of this study showed that the PCOS group
had significantly higher levels of insulin, insulin resist-
ance, glucose, all plasma lipids except HDL-C, com-
pared to the healthy controls, while insulin secretion
was not different. Among the anthropometric variables,
the two groups were very similar and only differed in
the WHR ratio, which was significantly higher in the
PCOS patients.
The abnormalities in lipid, insulin, and HOMA-IR, seen
in this study confirm previous reports, which show that
PCOS patients have altered lipidograms with high LDL-C,
most probably due to the insulin resistance phenotype
and altered BMI, rather than circulating androgen levels
[38]. This evidence might recall some recent data on Bra-
zilian adolescent women, where the existence of more
than one risk factor for type 2 diabetes mellitus showed a
high HOMA-IR and a low HOMA-S [39].
Both leptin and ghrelin did not show any differences
between the two groups. Hence, our findings could not
confirm the earlier reports by Mitkov et al. [17] and
Pehlivanov et al. [18] and other researchers [19, 20, 22],
who reported an elevated level of leptin in PCOS
Table 2 Comparison of the anthropometric measurements and metabolic profile of lean and obese patients with polycystic ovary
syndrome (POCS) and lean and obese controls
Parameter Patient Group Mean SD p1 Control Group Mean SD p2 p3
Age (years) Lean 26.05 0.63 0.131 Lean 23.95 0.60 0.231 0.018
Obese 27. 24 0.48 Obese 25.14 0.79 0.028
Body mass index (BMI) (kg/m2) Lean 22.86 0.20 0.0001 Lean 20.85 0. 24 < 0.0001 < 0.0001
Obese 33.64 0.62 Obese 34.47 0.72 0.387
Weight/height ratio Lean 0.79 0.01 0.0001 Lean 0.71 0.006 < 0.0001 < 0.0001
Obese 0.88 0.01 Obese 0.81 0.007 < 0.0001
Cholesterol (mmol/L) Lean 3.91 0.06 0.0001 Lean 3.42 0.05 < 0.0001 < 0.0001
Obese 4.68 0.11 Obese 3.86 0.07 < 0.0001
Triglyceride (mmol/L) Lean 0.93 0.05 0.0001 Lean 0.68 0.029 < 0.0001 < 0.0001
Obese 1.21 0.05 Obese 1.04 0.057 0.025
HDL-C (mmol/L) Lean 1.04 0.04 0.132 Lean 1.44 0.040 < 0.0001 < 0.0001
Obese 1.11 0.04 Obese 1.12 0.038 0.945
LDL-C (mmol/L) Lean 2.20 0.04 0.0001 Lean 1.31 0.048 < 0.0001 < 0.0001
Obese 2.65 0.09 Obese 2.11 0.078 < 0.0001
Leptin Lean 13.65 0.40 0.0001 Lean 11.70 0.464 < 0.0001 < 0.0001
Obese 35.78 1.78 Obese 39.94 2.59 0.181
Fasting ghrelin Lean 0.53 0.02 0.0001 Lean 0.57 0.016 < 0.0001 0.025
Obese 0.33 0.01 Obese 0.33 0.014 0.767
Fasting insulin (pmol/L) Lean 86.67 8.20 0.04 Lean 52.57 02.28 < 0.0001 < 0.0001
Obese 107.68 6.45 Obese 93.51 5. 37 0.094
Fasting Glucose (mmol) Lean 4.93 0.05 0.014 Lean 4.53 0.051 < 0.0001 < 0.0001
Obese 5.15 0.07 Obese 4.88 0.066 0.007
HOMA-IR (insulin resistance) Lean 2.807 0.27 0.034 Lean 1.49 0.070 < 0.0001 < 0.0001
Obese 3.492 0. 25 Obese 2.88 0.177 0.05
HOMA-S (insulin secretion) Lean 164.80 16.64 0.146 Lean 161.06 10.62 0.013 0.850
Obese 194. 25 11.97 Obese 207.19 14.64 0.49
p1 = significance of the difference between lean and obese PCOS
p2 = significance of the difference between lean and obese control
p3 = significance of the difference between lean PCOS vs lean control and obese PCOS vs obese control
HOMA Homeostatic model assessment
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patients. As a matter of fact, controversial results have
been reported for serum leptin levels in PCOS patients,
where both high concentrations and unchanged levels
have been documented in different studies, though novel
parameters, such as the ratio adiponectin/leptin, appear to
be more promising to associate PCOS with serum circu-
lating adipokines [4, 40, 41]. These controversial results
have been explained by differences in age, anthropometric
differences, genetics and disease severity [42, 43].
Leptin has a dual effect on reproduction, where ele-
vated levels of this hormone may have a pathophysio-
logical role in the development of PCOS. A positive
effect of leptin is in its role as a trigger of puberty on a
hypothalamic-pituitary axis by stimulating estrogen
Table 3 Correlation between leptin levels and clinical and
metabolic profile of patients with polycystic ovary syndrome
(POCS) and healthy controls
Correlation of
leptin levels and
PCOS (n = 130) Control (n = 122)
r p r p
Age 0.092 0.2979 0.045 0.6226
Body mass index (BMI) 0.289 0.0009** 0.187 0.0392*
Weight/height ratio 0.213 0.0150* 0.096 0.2929
Cholesterol 0.204 0.0199* 0.043 0.6382
Triglyceride 0.175 0.0464* 0.024 0.7930
HDL-C −0.202 0.0212* 0.037 0.6858
LDL-C 0.235 0.0071* 0.049 0.5920
Glucose 0.135 0.1257 0.121 0.1843
Insulin 0.382 0.0001** 0.254 0.0048*
Ghrelin − 0.251 0.0040* − 0.248 0.0059*
HOMA-IR (insulin resistance) 0.316 0.0001** 0.611 < 0.0001**
HOMA-S 0.175 0.046* 0.326 < 0.0001**
HOMA Homeostatic model assessment
*Significant (p < 0.05)
**Highly significant (p < 0.001)
Table 4 Correlation between ghrelin levels and clinical and
metabolic profile of patients with polycystic ovary syndrome
(POCS) and healthy controls
Correlation of
ghrelin levels and
PCOS (n = 130) Control (n = 122)
r p r p
Age 0.108 0.2213 0.118 0.1955
Body mass index (BMI) −0.292 0.0007** − 0.196 0.0305*
Weight/height ratio −0.209 0.0170* 0.114 0.2112
Cholesterol −0.215 0.0140* 0.048 0.5996
Triglyceride −0.199 0.0232* 0.019 0.8354
HDL-C 0.207 0.0181* 0.021 0.8184
LDL-C −0.229 0.0088* 0.071 0.4371
Glucose 0.129 0.1435 0.109 0.2320
Insulin −0.347 0.0001** − 0.251 0.0053*
Leptin −0.251 0.0040* −0.248 0.0059*
HOMA-IR (insulin resistance) −0.279 0.001** − 0.637 < 0.0001**
HOMA-S (insulin secretion) − 0.293 0.001** − 0.257 0.004**
HOMA Homeostatic model assessment
*Significant (p < 0.05)
**Highly significant (p < 0.001)
Table 5 Correlation of homeostatic model assessment for
insulin resistance (HOMA-IR) and the clinical and metabolic
profile of patients with polycystic ovary syndrome (POCS) and
healthy controls
Correlation between
HOMA-IR and:
PCOS Control
r p r p
Age −0.183 0.038* 0.144 0.115
Body mass index (BMI) 0.342 0.0001** 0.634 < 0.0001**
Weight/height ratio 0.212 0.024* 0.518 < 0.0001**
Cholesterol 0.168 0.057 0.382 < 0.0001**
Triglyceride 0.325 0.0001** 0.350 < 0.0001**
HDL-C −0.210 0.016* −0.389 < 0.0001**
LDL-C 0.268 0.002** 0.529 < 0.0001**
Leptin 0.316 0.0001** 0.611 < 0.0001**
fasting ghrelin −0.279 0.001** −0.637 < 0.0001**
Fasting insulin 0.970 0.0001** 0.984 < 0.0001**
Fasting glucose 0.463 0.0001** 0.560 < 0.0001**
HOMA-S (insulin secretion) 0.698 0.0001** 0.405 < 0.0001**
*Significant (p < 0.05)
** Highly Significant (p < 0.001)
Table 6 Correlation of homeostasis model assessment of insulin
sensitivity (HOMA-S) and the clinical and metabolic profile of
patients with polycystic ovary syndrome (POCS) and healthy
controls
Correlation between
HOMA-S and:
PCOS Control
r p r p
Age −0.320 < 0.0001** 0.074 0.420
Body mass index (BMI) 0.194 0.027* 0.317 < 0.0001**
Weight/height ratio 0.180 0.056 0.343 < 0.0001**
Cholesterol 0.079 0.370 0.145 0.111
Triglyceride 0.185 0.035* 0.153 0.095
HDL-C −0.265 0.002** −0.118 0.199
LDL-C 0.175 0.047* 0.168 0.065
Leptin 0.175 0.046* 0.326 < 0.0001**
Fasting ghrelin −0.293 0.001** −0.257 0.004**
Fasting insulin 0.832 < 0.0001** 0.540 < 0.0001**
Fasting glucose −0.210 0.017* −0.415 < 0.0001**
HOMA-IR (insulin resistance) 0.698 < 0.0001** 0.405 < 0.0001**
*Significant (p < 0.05)
** Highly Significant (p < 0.001)
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secretion, and the negative impact of leptin, in condi-
tions such as hyperleptinemia, is the inhibition of the
ovarian response to gonadotrophin stimulation [44].
When the obese PCOS patients were separated from
the lean PCOS patients, and the results were compared
with the obese and lean controls, respectively, the lean
PCOS had all parameters significantly different com-
pared to the lean controls except for HOMA-S. On the
other hand, when the obese PCOS were compared to
the obese control, the significant differences were lost
between the two groups in BMI, leptin, ghrelin, insulin,
HDL-C and HOMA-S, but the differences persisted in
all the lipids, in glucose level and insulin resistance.
These results demonstrate that PCOS is associated with
hyperinsulinemia, insulin resistance and elevated glucose
and lipids, but as the BMI increases the differences in lep-
tin, ghrelin, insulin, HDL-C, and insulin secretion are lost,
indicating that BMI, plays a major role in relating to these
abnormalities even in the control group.
Several interesting correlations were identified when
ghrelin, leptin, HOMA-IR and HOMA-S levels were cor-
related with the biochemical and hormonal parameters in
the PCOS patients and controls. The association between
leptin and the lipids were significant in the PCOS, but not
in the controls. These results indicate very clearly that
even though leptin levels do not differ between the PCOS
and controls, but the leptin levels significantly correlate
with elevating lipids, insulin, ghrelin, insulin resistance
and insulin secretion. The findings of the present study
confirm the result of previous studies, which have shown
a significant correlation between WHR with leptin in the
PCOS patients [45, 46]. This supports the importance of
abdominal fat mass in the secretion of leptin and hence in
the resulting lipid abnormalities which exist in the PCOS.
Ghrelin correlated with the same parameters as leptin, ex-
cept that the correlations were inverse. The WHR was sig-
nificantly higher in the PCOS group, both lean and obese
group compared to the counterpart control groups. These
results further confirm the importance of the abdominal
fat in PCOS.
Insulin resistance is a frequent finding in PCOS and the
PCOS patients in this study had higher levels of
HOMA-IR compared to the control group. Correlation
studies between HOMA-IR and the clinical and biochem-
ical parameters showed several correlations in both pa-
tients and controls, except between HOMA-IR and
cholesterol in the patient group, there was no relationship.
These results indicate that insulin resistance plays a sig-
nificant role in the associated hormonal and biochemical
abnormalities observed in PCOS patients [10, 47–49].
Insulin secretion as judged from the level of HOMA-S
did not differ between the PCOS patients and controls
(p > 0.05), and comparison between PCOS lean and
obese females did not show any significance (Table 2).
This study is important as it has highlighted several dif-
ferences in the results of Saudi PCOS patients compared
to studies reported in literature. It has also shown signifi-
cant differences between the obese and lean PCOS pa-
tients. Though this study has covered several parameters,
the major limitation of this study is that coagulation
parameters and liver functions were not investigated, and
hence the findings of previous studies, related to these
parameters, could not be confirmed in Saudis.
Further studies are warranted on a larger group of
PCOS patients in an attempt to confirm the role of liver
disorders and coagulation parameter abnormalities in
the pathogenesis of PCOS in Saudi patients.
Conclusion
This study investigated the relationship between leptin
and ghrelin in PCOS-affected Saudi women and showed
that leptin is probably associated with lipidograms
(particularly with chol-LDL) in PCOS patients, as ex-
pected, but that the difference in serum adipokines levels
between lean and obese female with PCOS, is no more
significant, most probably due to an interference of
insulin level and HOMA indexes [50–58]. It may be
concluded that leptin or ghrelin levels in the serum are
associated with insulin metabolism and insulin resist-
ance and the lipidogram pattern and BMI is a conse-
quence of the insulin metabolic impairment. This
evidence is supported by the interesting data from
HOMA-S.
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